Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:AGE

AgeX Therapeutics (AGE) Stock Price, News & Analysis

AgeX Therapeutics logo

About AgeX Therapeutics Stock (NYSE:AGE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.22
$16.51
52-Week Range
N/A
Volume
3,700 shs
Average Volume
3,849 shs
Market Capitalization
$11.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGE Stock News Headlines

Serina Therapeutics initiated with a Buy at JonesResearch
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Serina Therapeutics sells UniverXome subsidiary
Serina Therapeutics Inc (SER)
Serina Therapeutics to Present at the 14th Annual Injectables Summit
Russell Skibsted's Net Worth
See More Headlines

AGE Stock Analysis - Frequently Asked Questions

Shares of AgeX Therapeutics split on Monday, March 18th 2024.The 8-5 split was announced on Monday, March 18th 2024. The newly issued shares were payable to shareholders after the market closes on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that AgeX Therapeutics investors own include Allena Pharmaceuticals (ALNA), Biocept (BIOC), Palatin Technologies (PTN), Aadi Bioscience (AADI), Arbutus Biopharma (ABUS) and Adamis Pharmaceuticals (ADMP).

Company Calendar

Today
7/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:AGE
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.80 million
Net Margins
-10,424.65%
Pretax Margin
-10,430.28%

Debt

Sales & Book Value

Annual Sales
$140 thousand
Price / Cash Flow
N/A
Book Value
($16.07) per share
Price / Book
N/A

Miscellaneous

Free Float
1,008,000
Market Cap
$11.99 million
Optionable
Not Optionable
Beta
1.18
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NYSE:AGE) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners